MX2007014920A - Combination therapy comprising diaryl ureas for treating diseases. - Google Patents

Combination therapy comprising diaryl ureas for treating diseases.

Info

Publication number
MX2007014920A
MX2007014920A MX2007014920A MX2007014920A MX2007014920A MX 2007014920 A MX2007014920 A MX 2007014920A MX 2007014920 A MX2007014920 A MX 2007014920A MX 2007014920 A MX2007014920 A MX 2007014920A MX 2007014920 A MX2007014920 A MX 2007014920A
Authority
MX
Mexico
Prior art keywords
combination therapy
treating diseases
diaryl ureas
diaryl
ureas
Prior art date
Application number
MX2007014920A
Other languages
Spanish (es)
Inventor
Urban Scheuring
Ingo Bernard
Claus Garbe
Birgit Schittek
Friedegund Meier
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MX2007014920A publication Critical patent/MX2007014920A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to pharmaceutical compositions and combinations for treating cancer, comprising a diaryl urea compound and an PI3K/AKT signaling pathway inhibitor. Useful combinations include e.g. BAY-43-9006 as a diaryl urea compound.
MX2007014920A 2005-05-27 2006-05-13 Combination therapy comprising diaryl ureas for treating diseases. MX2007014920A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05011476 2005-05-27
EP05011475 2005-05-27
EP05011478 2005-05-27
PCT/EP2006/004523 WO2006125539A2 (en) 2005-05-27 2006-05-13 Combination therapy comprising diaryl ureas for treating diseases

Publications (1)

Publication Number Publication Date
MX2007014920A true MX2007014920A (en) 2008-04-09

Family

ID=37052960

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007014920A MX2007014920A (en) 2005-05-27 2006-05-13 Combination therapy comprising diaryl ureas for treating diseases.

Country Status (10)

Country Link
US (1) US20090306020A1 (en)
EP (1) EP1888065A2 (en)
JP (1) JP2008545670A (en)
KR (1) KR20080012902A (en)
AU (1) AU2006251428A1 (en)
BR (1) BRPI0610090A2 (en)
CA (1) CA2609387A1 (en)
IL (1) IL187085A0 (en)
MX (1) MX2007014920A (en)
WO (1) WO2006125539A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2475703C (en) 2002-02-11 2016-12-20 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
UY28213A1 (en) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp NEW CYANOPIRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS.
CA2526617C (en) 2003-05-20 2015-04-28 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
PL1663978T3 (en) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
ES2351612T3 (en) * 2005-03-07 2011-02-08 Bayer Schering Pharma Aktiengesellschaft PHARMACEUTICAL COMPOSITION THAT INCLUDES A DIFFENILUREA REPLACED WITH OMEGA-CARBOXIARIL FOR THE TREATMENT OF CANCER.
AR062927A1 (en) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4- ([[4- CHLORINE-3- (TRIFLUOROMETILE) PHENYL) CARBAMOIL] AMINO] -3- FLUOROPHENOXY) -N- METHYLPIRIDIN-2-MONOHIDRATED CARBOXAMIDE
WO2008070100A1 (en) * 2006-12-05 2008-06-12 University Of South Florida Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
WO2008089389A2 (en) 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
US7947723B2 (en) 2008-02-01 2011-05-24 Spelman College Synthesis and anti-proliferative effect of benzimidazole derivatives
WO2009126415A1 (en) * 2008-04-09 2009-10-15 Dow Global Technologies Inc. Multi-stage process and apparatus for recovering dichlorohydrins
TW201012467A (en) * 2008-09-16 2010-04-01 Taiho Pharmaceutical Co Ltd Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid
JP2012523429A (en) * 2009-04-09 2012-10-04 オンコシレオン，インコーポレイテッド Methods and PI-3 kinase inhibitor compositions for treating fibrosis
CN105063001A (en) 2009-09-16 2015-11-18 新基阿维罗米克斯研究公司 Protein kinase complex, pharmaceutical composition containing the same and use thereof
AU2010339456A1 (en) 2009-12-30 2012-07-05 Celgene Avilomics Research, Inc. Ligand-directed covalent modification of protein
ES2385276B1 (en) * 2010-02-25 2013-07-05 Universidad Del País Vasco COMPOUNDS FOR THE TREATMENT OF ALZHEIMER.
EP2595628A1 (en) 2010-07-19 2013-05-29 Bayer HealthCare LLC Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
EP3082800B1 (en) 2013-12-20 2022-02-02 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
CN114751899B (en) * 2022-04-24 2024-03-29 贵州医科大学 Diaryl urea mTOR kinase inhibitor, and pharmaceutical composition and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378725A (en) * 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2475703C (en) * 2002-02-11 2016-12-20 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
CA2481229C (en) * 2002-04-08 2010-09-21 Merck & Co., Inc. Substituted pyrazine inhibitors of akt
PL1663978T3 (en) * 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
BRPI0508970A (en) * 2004-03-19 2007-08-21 Penn State Res Found combinatorial methods and compositions for the treatment of melanoma
WO2006027346A2 (en) * 2004-09-06 2006-03-16 Altana Pharma Ag Novel pyrazolopyrimidines

Also Published As

Publication number Publication date
BRPI0610090A2 (en) 2008-12-09
JP2008545670A (en) 2008-12-18
KR20080012902A (en) 2008-02-12
EP1888065A2 (en) 2008-02-20
US20090306020A1 (en) 2009-12-10
IL187085A0 (en) 2008-08-07
AU2006251428A1 (en) 2006-11-30
WO2006125539A2 (en) 2006-11-30
WO2006125539A3 (en) 2007-03-08
CA2609387A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
MX2007014920A (en) Combination therapy comprising diaryl ureas for treating diseases.
TW200738234A (en) Triazole compounds that modulate HSP90 activity
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
DE602006016449D1 (en)
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2007002398A (en) New pharmaceutical compositions for the treatment of cancer.
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
GEP20125469B (en) Inhibitors of akt activity
TW200637831A (en) Triazole compounds that modulate Hsp90 activity
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
TW200738659A (en) Novel compounds
MX2010001565A (en) Triazole compounds that modulate hsp90 activity.
MX2009008547A (en) Triazole compounds that modulate hsp90 activity.
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
TW200732296A (en) Novel compounds
TW200800999A (en) Novel compounds
MX2009007944A (en) Compounds and compositions as kinase inhibitors.
MX2009006704A (en) New compounds.
GB0625648D0 (en) Compounds
TW200612892A (en) Novel compounds
TW200744586A (en) Therapeutic compounds
MX2008002166A (en) Compounds and compositions as tpo mimetics.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal